Grünenthal, an R&D-driven, privately held international pharmaceutical company in Germany has acquired Pittsburgh company Thar Pharmaceuticals to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease.
